Page 82 - 2020_02-Haematologica-web

I. Yakoub-Agha et al.
67. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448.
68. Dai H, Zhang W, Li X, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmuno- logy. 2015;4(11):e1027469.
69. Kebriaei P, Singh H, Huls MH, et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016;126(9):3363-3376.
70. Anwer F, Shaukat AA, Zahid U, et al. Donor origin CAR T cells: graft versus malignancy effect without GVHD, a sys- tematic review. Immunotherapy. 2017;9(2):123-130.
71. Hill JA, Li D, Hay KA, et al. Infectious com- plications of CD19-targeted chimeric anti- gen receptor-modified T-cell immunothera-
py. Blood. 2018;131(1):121-130.
72. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T
cells. Blood. 2012;119(12):2709-2720.
73. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and man- agement of cytokine release syndrome.
Blood. 2014;124(2):188-195.
74. Brudno JN, Kochenderfer JN. Toxicities of
chimeric antigen receptor T cells: recogni- tion and management. Blood. 2016;127(26):3321-3330.
75. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(3):348- 371.
76. European Medicines Agency. CAR T cell
therapy registries workshop. 2019 [cited; Available from: https://www.ema.europa.eu /en/documents/report/report-car-t-cell- therapy-registries-workshop_en.pdf
77. European Medicines Agency. Qualification opinion on cellular therapy module of the European Society for Blood & Marrow Transplantation (EBMT) Registry. 2019 February 28, 2019 [cited; Available from: https://www.ebmt.org/ebmt/news/ebmt- receives-regulatory-qualification-european- medicine-agency-ema-use-its-patient
78. Snowden JA, McGrath E, Duarte RF, et al. JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement. Bone Marrow Transplant. 2017;52(10):1367- 1371.
79. Saccardi R, McGrath E, Snowden AJ. JACIE accreditation of HSCT programs. The EBMT Handbook. 2019:35-40.
316
haematologica | 2020; 105(2)